Edwards Lifesciences Co. (NYSE:EW) Shares Bought by APG Asset Management N.V.

APG Asset Management N.V. grew its holdings in Edwards Lifesciences Co. (NYSE:EW) by 2.9% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 492,537 shares of the medical research company’s stock after acquiring an additional 13,832 shares during the quarter. APG Asset Management N.V.’s holdings in Edwards Lifesciences were worth $42,450,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of the business. Crewe Advisors LLC acquired a new stake in Edwards Lifesciences in the 1st quarter worth approximately $28,000. First Community Trust NA acquired a new stake in shares of Edwards Lifesciences during the second quarter worth $29,000. Riverview Trust Co acquired a new stake in shares of Edwards Lifesciences during the first quarter worth $34,000. Webster Bank N. A. acquired a new position in shares of Edwards Lifesciences in the 2nd quarter valued at $39,000. Finally, Rise Advisors LLC raised its stake in Edwards Lifesciences by 125.0% in the 1st quarter. Rise Advisors LLC now owns 477 shares of the medical research company’s stock worth $46,000 after acquiring an additional 265 shares during the last quarter. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 5,000 shares of Edwards Lifesciences stock in a transaction on Wednesday, August 14th. The shares were sold at an average price of $66.08, for a total transaction of $330,400.00. Following the sale, the vice president now owns 46,936 shares of the company’s stock, valued at approximately $3,101,530.88. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other Edwards Lifesciences news, VP Daveen Chopra sold 1,250 shares of the business’s stock in a transaction on Tuesday, August 20th. The stock was sold at an average price of $69.95, for a total transaction of $87,437.50. Following the transaction, the vice president now owns 29,333 shares of the company’s stock, valued at $2,051,843.35. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the firm’s stock in a transaction on Wednesday, August 14th. The stock was sold at an average price of $66.08, for a total value of $330,400.00. Following the completion of the sale, the vice president now directly owns 46,936 shares of the company’s stock, valued at $3,101,530.88. The disclosure for this sale can be found here. In the last ninety days, insiders sold 16,250 shares of company stock valued at $1,218,138. 1.29% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on EW shares. StockNews.com lowered Edwards Lifesciences from a “buy” rating to a “hold” rating in a report on Thursday, July 25th. UBS Group cut their price target on shares of Edwards Lifesciences from $90.00 to $75.00 and set a “neutral” rating on the stock in a report on Tuesday, September 10th. Jefferies Financial Group cut shares of Edwards Lifesciences from a “buy” rating to a “hold” rating and decreased their price objective for the company from $85.00 to $70.00 in a research note on Wednesday, September 18th. JPMorgan Chase & Co. cut shares of Edwards Lifesciences from an “overweight” rating to a “neutral” rating and reduced their target price for the stock from $105.00 to $72.00 in a report on Thursday, July 25th. Finally, Piper Sandler lowered their price target on shares of Edwards Lifesciences from $88.00 to $73.00 and set a “neutral” rating on the stock in a report on Thursday, July 25th. Sixteen equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $79.82.

Edwards Lifesciences Stock Up 1.2 %

EW stock opened at $66.58 on Friday. Edwards Lifesciences Co. has a 52 week low of $58.93 and a 52 week high of $96.12. The company has a quick ratio of 2.87, a current ratio of 3.71 and a debt-to-equity ratio of 0.08. The firm has a 50-day simple moving average of $68.18 and a 200-day simple moving average of $82.19. The stock has a market capitalization of $40.12 billion, a P/E ratio of 28.70, a P/E/G ratio of 2.80 and a beta of 1.13.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Wednesday, July 24th. The medical research company reported $0.70 EPS for the quarter, topping the consensus estimate of $0.69 by $0.01. The company had revenue of $1.63 billion during the quarter, compared to analyst estimates of $1.65 billion. Edwards Lifesciences had a return on equity of 22.35% and a net margin of 24.55%. Edwards Lifesciences’s quarterly revenue was up 6.7% on a year-over-year basis. During the same period in the previous year, the business earned $0.66 EPS. Equities analysts forecast that Edwards Lifesciences Co. will post 2.71 earnings per share for the current fiscal year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.